Daniela Shveid Gerson

Daniela Shveid Gerson

Auto-generated profile, based on publicly available information

Daniela Shveid Gerson

Cancer Center, ABC Medical Center, México City, Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
DGDaniela Shveid Gerson
Daniela Shveid Gerson
RGRaquel Gerson‐Cwilich
Raquel Gerson‐Cwilich
CTCesar Octavio Lara Torres
Cesar Octavio Lara Torres
AKAlberto Chousleb de Kalach
Alberto Chousleb de Kalach
JGJosé Luis Ventura Gallegos
José Luis Ventura Gallegos
AZAlejandro Zentella‐Dehesa
Alejandro Zentella‐Dehesa
Introduction: Obesity has been associated with an increased risk of biologically aggressive variants in breast cancer. Women with obesity often have tumors diagnosed at later stages of the disease, associated with a poorer prognosis and a different response to treatment. Human cell lines have been derived from specific subtypes of breast cancer and have served to define the cell physiology of corresponding breast cancer subtypes. However, there are no current cell lines for breast cancer specifically derived from patients with different BMIs. The availability of those breast cancer cell lines should allow to describe and unravel functional alterations linked to these comorbidities. Methods: Cell cultures were established from tumor explants. Once generated, the triple negative subtype in a patient with obesity and a patient with a normal BMI were chosen for comparison. For cellular characterization, the following assays were conducted: proliferation assays, chemo – sensitivity assays for doxorubicin and paclitaxel, wound healing motility assays, matrix invasion assays, breast cancer cell growth to estradiol by chronic exposure to leptin, induction of endothelial permeability and tumorigenic potential in athymic mice with normo - versus hypercaloric diets with an evaluation of the epithelium – mesenchymal transformation proteins.Results: Two different cell lines, were established from patients with breast cancer: DSG-BC1, with a BMI of 21.9 kg/m2 and DSG-BC2, with a BMI of 31.5 kg/m2. In vitro, these two cell lines show differential growth rates, motility, chemosensitivity, vascular permeability, response to leptin with an activation of the JAK2/STAT3/AKT signaling pathway. In vivo, they displayed distinct tumorigenic potential. In particular, DSG-BC2, presented higher tumorigenicity when implanted in mice fed with a hypercaloric diet.Discussion: To our knowledge, these primary cultures are the first in vitro representation of both breast cancer and obesity. DSG – BC2 presented a more aggressive in vivo and in vitro phenotype. These results support the hypothesis that breast cancer generated in an obese metabolic state may represent a contrasting variant within the same disease. This new model will allow both further comprehension, functional studies and the analysis of altered molecular mechanisms under the comorbidity of obesity and breast cancer.

6 August 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
DBDenisse Añorve Bailon
Denisse Añorve Bailon
JPJavier Picó-Guzmán
Javier Picó-Guzmán
SCSergio Cifuentes
Sergio Cifuentes
RTRogelio Trejo
Rogelio Trejo
JCJeronimo Rodríguez Cid
Jeronimo Rodríguez Cid
DGDaniela Shveid Gerson
Daniela Shveid Gerson
Introduction Lung cancer continues to be the leading cause of death among cancer patients worldwide. This study aimed to estimate the clinical, economic, and social burdens of stage IV non-small cell lung cancer (NSCLC) in private and public healthcare centers in Mexico, utilizing real-world evidence. Methods The study population included patients >18 years of age diagnosed with stage IV NSCLC who received cancer treatment at the Centro Médico Nacional Siglo XXI (IMSS), the Centro Médico Nacional “20 de Noviembre” (ISSSTE), the Mexican Institute of Respiratory Diseases (INER), and the Medical Center ABC (American British Cowdray) from 1 January 2019 to 31 December 2020. The analysis included evaluation of epidemiological data, treatment regimens, and clinical outcomes, and emphasized pharmacological and non-pharmacological treatments, including detailed follow-up investigations, as part of comprehensive clinical management. Additionally, the study assessed the social burden through variables such as working-age absenteeism and presenteeism and caregiver productivity loss, as well as economic burden, considering both clinical and social components, with costs adjusted to 2022 Mexican pesos (MXN) values. Results A total of 188 patients with metastatic NSCLC were studied. The main type of NSCLC tumor found in the sample was adenocarcinoma (81%). Treatment regimens included pharmacological treatments (78%), non-pharmacological treatments (25%), and palliative care (24%). Complications were present in 73% of the cohort, while 60% presented adverse events. Clinical management costs of up to MXN1,001,579 per patient in the public sector and MXN2,140,604 in the private sector were reported. It was estimated that working-age patients lose 84–335 days yearly due to absenteeism and presenteeism, while caregivers report a productivity loss equivalent to 13–30 days due to the management of NSCLC patients. These indirect costs of NSCLC contribute to the social burden. A working-age patient with stage IV disease is associated with an average indirect cost of MXN49,731–178,287 in public institutions, while in private institutions, the cost elevates to MXN438,103. Conclusions This study highlights the substantial clinical, economic, and social burdens of stage IV NSCLC in Mexico, revealing significant disparities between public and private healthcare sectors. It underscores the urgent need for standardized practices and equitable care across all systems.

1 January 2021 in Anales Médicos de la Asociación Médica del Centro Médico ABC
Verified
Journal Article
Closed access
PDF file
RCRaquel Gerson Cwilich
Raquel Gerson Cwilich
ADAlejandro Zentella Dehesa
Alejandro Zentella Dehesa
HGHéctor Murrieta González
Héctor Murrieta González
LALaura Daniela Campos Alvarado
Laura Daniela Campos Alvarado
ELEric Alejandro García López
Eric Alejandro García López
ARAlejandro Noguez Ramos
Alejandro Noguez Ramos

1 December 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
ISIlana Schlam
Ilana Schlam
Kelly A. HirkoKelly A. Hirko
Kelly A. Hirko
DSDaniela Shveid
Daniela Shveid
IAInas Abuali
Inas Abuali
SSSarah Sewaralthahab
Sarah Sewaralthahab
Dario TrapaniDario Trapani
Dario Trapani
PURPOSE: Trimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM), and postmastectomy radiation therapy. Although broadly considered the best approach for IBC, in the United States, only a third of patients receive TMT. The rate is unknown in low- and middle-income countries (LMICs). METHODS: A questionnaire in English and Spanish was constructed to assess the awareness, knowledge, and treatment patterns of IBC among providers in LMICs. It was emailed to the ONCOLLEGE global oncology collaborative group (a network of cancer care providers practicing in LMICs) and through other oncology network providers in LMICs, enhancing the sample size through a snowball sampling approach. RESULTS: Between June and December of 2023, 145 participants completed the questionnaire, of whom 112 respondents were from 36 LMICs. All the providers reported that standard chemotherapy and MRM were available in their practice; 99.5% responded that radiation therapy was available. A total of 74.1% appropriately reported that IBC is a clinical diagnosis, although 51.8% stated that pathologic evidence of lymphatic emboli was required for IBC diagnosis. A third of the providers responded that >90% of their patients undergo all three parts of TMT. CONCLUSION: Many patients with IBC in LMICs are not receiving TMT. Barriers to diagnosis and treatment were at least partially related to limited providers' comfort level and knowledge, suggesting that educational approaches can be impact-oriented interventions. On the basis of our findings, we created educational material, which will be translated into various languages and disseminated broadly to improve providers' awareness and knowledge of IBC.

12 May 2025 in Clinical Case Reports
Verified
Journal Article
Open access
DCDalia Cuenca
Dalia Cuenca
LSLatife Salame‐Khouri
Latife Salame‐Khouri
DSDaniela Shveid‐Gerson
Daniela Shveid‐Gerson
MAMarco Antonio Alegría‐Loyola
Marco Antonio Alegría‐Loyola
MMMoises Mercado
Moises Mercado
A 25‐year‐old previously healthy man presents to the clinic with a severe headache after cocaine consumption. Physical examination revealed acromegaloid features, and the hormonal profile revealed an IGF‐1 of 308 ng/mL (40.8 nmol/L) (normal reference range 197–333 ng/mL; 17.8–45.6). An MRI showed a heterogeneous, cystic lesion of the pituitary gland with hematic contents, consistent with the diagnosis of a pituitary apoplexy. Considering the normal IGF‐1 level, the patient was classified to be in remission, which deems it unnecessary to initiate pharmacologic or surgical treatment. Remission of acromegaly after a pituitary apoplexy is an extremely rare event, and pituitary apoplexy after cocaine consumption is also anecdotal. We present the first case of remission of acromegaly after a cocaine‐induced pituitary apoplexy.

1 February 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
TWTalia Wegman
Talia Wegman
LTLUCIA TAJA-CHAYEB
LUCIA TAJA-CHAYEB
ZZZyanya Lucia Zatarain-Barrón
Zyanya Lucia Zatarain-Barrón
CTCatalina Trejo-Becerril
Catalina Trejo-Becerril
DGDaniela Shveid Gerson
Daniela Shveid Gerson
ARAlejandro Ruíz-Patiño
Alejandro Ruíz-Patiño
Variations in somatic genetic alterations can be observed across different cancer types and diverse populations. Understanding the frequency of oncogenic variants in specific populations helps elucidate carcinogenesis and risk factors, with somatic variants often serving as treatment markers. Data regarding the somatic landscape across the main tumor subtypes in patients from Latin America and the Caribbean (LAC) have increased recently, highlighting important differences from contrasting populations in North America, Europe, and Asia. Many of these differences have pressing implications regarding screening, risk factor management, targeted therapies, and health care policy. This review aims to synthesize the existing information on somatic oncogenic variants in patients' tumors from LAC. We included the frequency of somatic oncogenic variants of the most frequent tumors in LAC: prostate cancer, female breast cancer, colon cancer, gastric cancer, and lung cancer. Furthermore, we add information from tumors that are relevant in LAC because of their high incidence, specific subtypes, or aggressive phenotypes, namely gallbladder cancer, acral melanoma, and hematologic neoplasms, respectively. The data highlight distinct differences in the reported prevalences of various somatic variants across a spectrum of neoplasms. Moreover, it demonstrates that an extensive number of genetic and molecular studies have been carried out in the region, improving the level of characterization for this complex, admixed population. Nonetheless, data from many individual countries are still scarce or altogether missing, underscoring the need to establish collaborative groups to further advance progress in LAC. The need for further comprehensive research in the area should not be substituted with data from other regions as we seek to empower the choices to improve our health care outlook.